Budigalimab (ABBV 181; PR 1648817) 是一种人源 IgG1 单克隆抗体，靶向程序性细胞死亡 1 (PD-1) 受体。Budigalimab 具有 Fc 突变，从而减少了 Fc 受体相互作用和效应因子的抑制作用。
| 生物活性 | Budigalimab (ABBV 181; PR 1648817) is a humanizedIgG1monoclonal antibody targetingprogrammed cell death 1(PD-1)receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function[1]. |
| IC50& Target | programmed cell death 1 (PD-1) receptor[1] |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
